SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin ($LTC) is trending amidst active community discussion, fueled by anticipation of broader crypto market uptrends and observed bullish technical chart patterns. Many enthusiasts are forecasting significant future appreciation, often highlighting its utility as a faster and more cost-effective digital currency compared to Bitcoin. However, a segment of the community remains skeptical, citing historical performance concerns and questioning its long-term potential.

Polygon

Polygon (POL) is actively trending amid increasing on-chain usage, notable revenue growth, and a significant token burning mechanism that's driving scarcity. The community is bullish, comparing POL's potential to previous Solana rallies and highlighting its undervaluation as a leading Ethereum Layer 2 solution poised to dominate payments in an upcoming altcoin season.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as escalating geopolitical tensions underscore the critical need for a domestic rare earth supply chain, driving extensive community discussion around resource independence. Investors are keenly focused on USAR's integrated mine-to-magnet strategy, particularly its Stillwater plant and heavy rare earth assets, amid global supply chain concerns and ongoing discussions like those surrounding Greenland.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after receiving FDA approval for EMPAVELI in rare kidney diseases, sparking community excitement over its strong efficacy and blockbuster potential. Investors are closely watching for potential EU re-entry for SYFOVRE, driven by compelling 5-year GALE study data, as discussions continue about management's commercial execution and the company's significant undervaluation amid high short interest.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is experiencing a significant surge in trading volume and price, driven by recent news of a private placement and the expiration of its IPO lock-up period. The community is actively debating its potential for a substantial short squeeze and speculating on high price targets, with many comparing its parabolic rise to other low-float Hong Kong IPOs, while closely examining the details of the recent offering.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is seeing renewed attention as the defense sector rallies, propelled by discussions around a potential significant increase to the U.S. defense budget. Community sentiment highlights the sector's strength amid rising global tensions, with many pointing to a key agreement for Lockheed to substantially expand PAC-3 missile production capacity as a positive long-term driver for national security spending.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Achieve Life Sciences Inc.

Achieve Life Sciences is trending as community discussion intensifies around its cytisinicline treatment, following the FDA's grant of a National Priority Voucher for vaping cessation and the acceptance of its smoking cessation New Drug Application. Investors are actively debating potential expedited approvals and a possible strategic acquisition by a larger pharmaceutical firm, especially with major healthcare conferences creating a ripe environment for dealmaking and M&A.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is seeing intense discussion driven by its recent leadership transition and reports of a significant data breach, impacting investor sentiment. Despite a notable price pullback, many in the community are identifying buying opportunities, bullish on its robust subscription model and potential from recent analyst upgrades and a new Netflix video podcast partnership, while others remain concerned about market volatility and streaming sector competition.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to strong community excitement surrounding its advanced GaN and SiC power solutions, which are seen as critical for next-generation AI data centers and align with NVIDIA's 800V AI factory architecture. Investors are actively discussing the stock's substantial short interest, fueling speculation of a significant short squeeze, while also anticipating potential major news and strategic partnerships in the energy-efficient AI infrastructure sector.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is trending as investors digest mixed signals regarding defense contractor practices, with a strong focus on a potential significant increase in future U.S. defense spending and recent contract wins for advanced systems. Community sentiment highlights the company's robust earnings and order backlog, reinforcing optimism for the broader aerospace and defense sector amid persistent global geopolitical dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Wayne Pisano purchased 5,000 shares of Altimmune stock in a transaction on Thursday, January 8th. The stock was bought at an average price of...

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH

Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH. 

Why Are Investors Looking At Altimmune Stock?

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.read more...

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

<ul class="summary-bullets"><li>The drug, a 1:1 glucagon/GLP-1 dual-receptor agonist, targets patients with metabolic dysfunction-associated steatohepatitis (MASH).</li><li>Altimmune shared 48-week topline results in December 2025, indicating that continued pemvidutide treatment improved non-invasive tests.</li><li>The Phase-3 trial will test multiple pemvidutide doses over a 52-week treatment period.</li></ul>Altimmune, Inc. (ALT) announced on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) for its drug pemvidutide.The drug, a 1:1 glucagon/GLP-1 dual receptor agonist, targets patients suffering from metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition with limited treatment options.<h2 class="st-heading-2">How The Recognition Helps</h2>The designation is intended to boost the development and review of drugs that address serious or life-threatening illnesses and demonstrate early evidence of clinical benefit.&nbsp;The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis, along with improvements in liver fat and non-invasive fibrosis markers.<a href="https://stocktwits.com/symbol/ALT">Altimmune stock</a> traded over 14% higher in Monday’s premarket. However,&nbsp;on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘extremely low’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical Progress</h2>Altimmune shared 48-week topline results in December 2025, indicating that continued pemvidutide treatment improved non-invasive tests such as Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM) compared with placebo.&nbsp;Patients on the 1.8 mg dose experienced additional weight loss without a plateau, and the drug maintained a strong tolerability profile, with fewer discontinuations due to adverse events.<blockquote>“The FDA’s Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver disease.”-Jerry Durso, President and CEO, Altimmune</blockquote>Following a productive end-of-phase 2 meeting with the FDA, Altimmune finalized key parameters for a registrational Phase 3 trial in MASH patients with moderate-to-advanced liver fibrosis. The study will test multiple pemvidutide doses over a 52-week treatment period and incorporate biopsy-based results to support potential approval.&nbsp;ALT stock has declined by over 51% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-tsm-stock-jumping-over-3-premarket-today/cmxM1yjR4b0">Why Is TSM Stock Jumping Over 3% Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug 

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.

Equity

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.


3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Altimmune (NASDAQ:ALT) Director John Gill Purchases 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director John Gill bought 12,500 shares of the business's stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average cost of...

John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director John Gill purchased 12,500 shares of the business's stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat reports...

Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Jerome Benedict Durso acquired 12,500 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was purchased at an...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

Intense speculation surrounds an imminent acquisition or major partnership, with target valuations ranging from $3.5 billion to $15 billion, linked to the JPM conference.

Investors eagerly anticipate CEO Jerry Durso's strategic update or a partnership announcement at the J.P. Morgan Healthcare Conference, signaling the company's path forward.

Traders report frustration over persistent stock price suppression around the $4 mark, attributing it to dark pool activities and options expiration tactics by market makers.

Recent purchases by multiple directors, including new CEO Jerry Durso and industry veteran Wayne Pisano, are being interpreted as a strong bullish indicator for upcoming news.

Discussion highlights Pemvidutide's "Best-in-Class" potential for MASH, specifically its muscle-sparing benefits, optimal GLP-1/GCGR ratio, and strong BTD regulatory status.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.24	--	--	N/A
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT
Q4 '24	-$0.33	-$0.33	0.75%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALT News

ALTAltimmune Inc